Montazeri S Ali, De la Garza-Ramos Cynthia, Silver Claudia, Paz-Fumagalli Ricardo, Lewis Andrew R, Frey Gregory T, Toskich Beau B
Division of Interventional Radiology, Department of Radiology, Mayo Clinic Florida, 4500 San Pablo Rd S, Jacksonville, FL, 32224, USA.
Florida State University College of Medicine, Tallahassee, FL, USA.
Eur J Nucl Med Mol Imaging. 2025 Mar 11. doi: 10.1007/s00259-025-07179-1.
To determine comprehensive treatment parameters predictive of complete pathologic necrosis (CPN) in early-stage hepatocellular carcinoma (HCC) treated with glass microsphere radiation segmentectomy (RS).
This study is a secondary analysis of 61 tumors with available post-treatment imaging from a previously published cohort treated with RS using Yttrium-90-containing glass microspheres prior to liver transplantation. Post-treatment Bremsstrahlung SPECT-CT single-compartment, multi-compartment, and voxel-based dosimetry analyses were performed using dose confirmation software and compared between tumors that achieved CPN vs. non-CPN.
Median specific activity (SA [1242 vs. 867 Bq, p = 0.018]), total angiosome dose (577 vs. 352 Gy, p = 0.005) tumor dose (1086 vs. 738 Gy, p = 0.007), and angiosome hepatic parenchymal dose (490 vs. 309 Gy, p = 0.005) were higher in the CPN (n = 43) vs. non-CPN (n = 18) cohort. Receiver operating characteristic (ROC) curve analyses (area under the curve [AUC], sensitivity, specificity) demonstrated that a SA ≥ 570 Bq (0.69, 88%, 50%), total angiosome dose ≥ 439 Gy (0.73, 70%, 67%), tumor dose ≥ 844 Gy (0.72, 76%, 67%), and angiosome hepatic parenchymal dose ≥ 420 Gy (0.73, 60%, 78%) were predictive of CPN (p < 0.05). No statistical difference was found between the tumor or angiosome particle density (PD), tumor volume, or angiosome volumes in the CPN and non-CPN cohorts. Subgroup ROC analysis of tumors that received SA < 570 Bq (n = 15) demonstrated that a total angiosome dose ≥ 263 Gy (0.85, 83%, 89%) and tumor dose ≥ 451 Gy (0.83, 100%, 67%) and were predictive of CPN (p < 0.05). An average angiosome PD ≥ 11.4 × 10/ml (AUC 0.81) was 83% sensitive and 79% specific to predict CPN in this subgroup (p < 0.05). 88% of tumors that were treated above all identified treatment parameter thresholds achieved CPN, compared to zero of those which did not meet a single criterion. Tumors fulfilling all single-compartment treatment parameter thresholds also met all multi-compartment dosimetry thresholds.
CPN was predicted by a SA of ≥ 570 Bq, total angiosome dose of ≥ 439 Gy, tumor dose of ≥ 844 Gy, and angiosome hepatic parenchymal dose ≥ 420 Gy. A total angiosome PD of ≥ 11.4 × 10/ml was associated with CPN in tumors treated with SA < 570 Bq. Both single-compartment and multi-compartment dosimetry had similar performance when optimized per the identified thresholds.
Not applicable.
确定玻璃微球放射切除术(RS)治疗早期肝细胞癌(HCC)时,预测完全病理坏死(CPN)的综合治疗参数。
本研究是对61例肿瘤的二次分析,这些肿瘤来自先前发表的队列,在肝移植前使用含钇-90的玻璃微球进行RS治疗,且有治疗后的影像资料。使用剂量确认软件对治疗后的轫致辐射单光子发射计算机断层扫描(SPECT-CT)进行单室、多室和基于体素的剂量分析,并在达到CPN与未达到CPN的肿瘤之间进行比较。
CPN组(n = 43)与非CPN组(n = 18)相比,中位比活度(SA [1242对867 Bq,p = 0.018])、总血管体剂量(577对352 Gy,p = 0.005)、肿瘤剂量(1086对738 Gy,p = 0.007)和血管体肝实质剂量(490对309 Gy,p = 0.005)更高。受试者工作特征(ROC)曲线分析(曲线下面积[AUC]、敏感性、特异性)表明,SA≥570 Bq(0.69,88%,50%)、总血管体剂量≥439 Gy(0.73,70%,67%)、肿瘤剂量≥844 Gy(0.72,76%,67%)和血管体肝实质剂量≥420 Gy(0.73,60%,78%)可预测CPN(p < 0.05)。CPN组和非CPN组在肿瘤或血管体颗粒密度(PD)、肿瘤体积或血管体体积方面未发现统计学差异。对接受SA < 570 Bq(n = 1十五)的肿瘤进行亚组ROC分析表明,总血管体剂量≥263 Gy(0.85,83%,89%)和肿瘤剂量≥451 Gy(0.83,100%,67%)可预测CPN(p < 0.05)。平均血管体PD≥11.4×10/ml(AUC 0.81)在该亚组中预测CPN的敏感性为83%,特异性为79%(p < 0.05)。在所有确定的治疗参数阈值以上接受治疗的肿瘤中,88%实现了CPN,而未达到任何一项标准的肿瘤中这一比例为零。满足所有单室治疗参数阈值的肿瘤也满足所有多室剂量分析阈值。
SA≥570 Bq、总血管体剂量≥439 Gy、肿瘤剂量≥844 Gy和血管体肝实质剂量≥420 Gy可预测CPN。在接受SA < 570 Bq治疗的肿瘤中,总血管体PD≥11.4×10/ml与CPN相关。当根据确定的阈值进行优化时,单室和多室剂量分析具有相似的性能。
不适用。